 879-882 (1996) 
Introduction
A number of human diseases may result, at least in part, from exposure to chemicals. A dose-response relationship between disease and chemical exposure, however, can be difficult to establish. Although the occurrence of disease can be recorded, humans are typically exposed to low levels of chemicals present in complex mixtures over extended periods. Lacking objective mea (1), for example, measured the exposure of animal feed production workers to the liver carcinogen aflatoxin B1 (AFB1) using serum albumin adducts. This group demonstrated the formation of AFB1 adducts with a detection limit of 5 pg/mg serum albumin using an enzyme-linked immunosorbent assay (ELISA). Other researchers have measured the exposure of workers to 2,4-difluoroaniline (2) and to ethylene oxide using Hb adducts (3). Goergens et al. (4) monitored fumigators for exposure to methyl bromide using methylated cysteine from Hb and serum albumin. This study detected exposure in workers despite their use of respiratory protection during fumigation operations.
Exposure to several dietary carcinogens has also been the subject of studies and monitoring method development. Many recent studies have focused on heterocyclic amines, some of which form adducts that may serve as acceptable biomarkers. In an assessment of human exposure to 3-amino-1 ,4-dimethyl-5 H-pyrido [4,3-b] indole, Umemoto et al. (5) detected Hb adducts formed from this material in human blood samples. Other researchers, however, have reported analytical methods for measurement of heterocyclic amine adducts that appear to be unsuitable for exposure assessment. Lynch et al. (6) examined the use of the serum albumin adducts of the foodborne heterocyclic amine 2-amino-3,8-dimethylimidazo [4,5-f] quinoxaline and were unable to detect this adduct in the blood of human volunteers. They attributed this to low levels of formation of the compound as well as to limited recovery in the analytical process.
The measurement of protein adducts can be quantitative if dose-dependent formation has been demonstrated, as is the case for a variety of adduct-forming compounds, including 4,4'-methylenedianiline (7) in rats and 7H-dibenz[c,g]carbazole in mice (8) . In humans, Vineis et al. (9) (9) used levels of 4ABP-Hb adducts to identify genetically determined slow acetylators, which had higher levels of this adduct. This reflected the decreased levels of detoxifying N-acetylation in these individuals.
The structure of blood protein adducts may also provide structural information about the reactive species responsible for adduct formation. Day et al. (20) (20, 21) . This study demonstrated the binding of the less toxic (-) enantiomer to histidine(146) and the more carcinogenic and mutagenic (+) enantiomer to carboxyl groups of aspartate(187) or glutamate(188) on human serum albumin (20) . Another study by Day et al. (22) 
Conclusions
Work continues on the development of methods that allow for practical applications of protein adduct measurement, such as those designed to assess exposure to chemicals as well as the effects of these exposures. The ability to measure blood protein adducts also provides a method of studying complex metabolic processes. In addition to advancing technology associated with a variety of analytical methods, these studies generate valuable information about the exposure to and metabolism of xenobiotics. Only a sampling of recent protein adduct work has been discussed; numerous studies have been carried out to identify and quantify protein adducts, to improve analytical techniques, and to apply these improvements to new settings and chemicals.
The information obtained in these studies must, however, be interpreted carefully. As the measurement becomes farther removed from the event for which it serves as a surrogate, an understanding of the biological mechanisms responsible for the adduct formation becomes increasingly important. The qualities that make blood protein adducts useful as biomarkers, such as access and stability, also demonstrate the differences between the measured adducts and the events for which they serve as markers. Target tissue DNA, for example, may be somewhat less accessible by a chemical and is subject to repair mechanisms. A linear relationship between levels of DNA adducts and those formed with blood proteins may not exist. Assigning value to blood protein adducts for this purpose may be a highly empirical process.
Relationships between disease risk and blood protein adduct levels may be even more difficult to establish. In addition to factors such as distribution and DNA repair, the development of disease, especially cancer, is not a simple process. According to the multistage model of carcinogenesis, for example, several events must take place for the development of disease. As a marker of DNA adduct formation that may lead to mutation events, a protein adduct may only serve to provide a marker for one part of a complex process. Cautious interpretation of these data is often required.
